| 2024年中报 | 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 药品贸易收入(元) | 27,520,330.01 | 57,720,034.27 | 34,781,783.08 | 70,811,584.07 | 35,722,505.75 |
| 注射液产品(元) | - | 11,823,821.61 | 11,240,865.85 | 30,522,453.61 | 15,966,758.08 |
| 综合制剂产品(元) | 97,119,158.13 | 171,568,534.49 | 92,084,558.99 | 175,316,197.66 | 101,193,508.70 |
| 其他业务收入(元) | - | 2,463,435.59 | - | - | - |
| 营业成本(元) | |||||
| 药品贸易收入(元) | 23,094,681.15 | 43,884,171.32 | 27,005,340.38 | 61,449,270.37 | 31,051,030.72 |
| 注射液产品(元) | - | 4,766,923.38 | 4,236,766.09 | 16,273,326.30 | 8,934,910.63 |
| 综合制剂产品(元) | 31,620,243.75 | 55,596,153.21 | 27,956,842.99 | 46,323,011.22 | 25,709,504.65 |
| 其他业务收入(元) | - | 311,819.71 | - | - | - |
| 毛利(元) | |||||
| 药品贸易收入(元) | 4,425,648.86 | 13,835,862.95 | 7,776,442.70 | 9,362,313.70 | 4,671,475.03 |
| 注射液产品(元) | - | 7,056,898.23 | 7,004,099.76 | 14,249,127.31 | 7,031,847.45 |
| 综合制剂产品(元) | 65,498,914.38 | 115,972,381.28 | 64,127,716.00 | 128,993,186.44 | 75,484,004.05 |
| 其他业务收入(元) | - | 2,151,615.88 | - | - | - |
| 毛利率(%) | |||||
| 药品贸易收入(%) | 16.08 | 23.97 | 22.36 | 13.22 | 13.08 |
| 注射液产品(%) | - | 59.68 | 62.31 | 46.68 | 44.04 |
| 综合制剂产品(%) | 67.44 | 67.60 | 69.64 | 73.58 | 74.59 |
| 其他业务收入(%) | - | 87.34 | - | - | - |
| 收入构成(%) | |||||
| 药品贸易收入(%) | 22.08 | 23.70 | 25.18 | 25.60 | 23.37 |
| 注射液产品(%) | - | 4.85 | 8.14 | 11.03 | 10.44 |
| 综合制剂产品(%) | 77.92 | 70.44 | 66.68 | 63.37 | 66.19 |
| 其他业务收入(%) | - | 1.01 | - | - | - |
| 毛利构成(%) | |||||
| 药品贸易收入(%) | 6.33 | 9.95 | 9.86 | 6.14 | 5.36 |
| 注射液产品(%) | - | 5.08 | 8.88 | 9.34 | 8.07 |
| 综合制剂产品(%) | 93.67 | 83.42 | 81.27 | 84.53 | 86.58 |
| 其他业务收入(%) | - | 1.55 | - | - | - |